Lupron Depot-PED® for Central Precocious Puberty: Diagnosis

Establishing the Diagnosis

Prompt identification of central precocious puberty (CPP) is important. CPP results from early onset of hypothalamic secretion of gonadotropin-releasing hormone (GnRH).¹ The majority of girls presenting with precocious puberty have CPP, with underlying neurological abnormalities being unusual;¹ in boys, central nervous system lesions are more common as the underlying cause of CPP.¹

In children with CPP, GnRH analog therapy is a highly effective treatment to stop the progression of puberty and to attempt to reclaim compromised growth potential.¹ The diagnosis of CPP may require:

Early pubertal changes.¹ Physical signs of puberty may include coarse, pigmented pubic hair. Girls may have premature breast development or genitalia changes (thicker vaginal mucosa). Pubertal signs in boys include growth of the penis and/or testicular growth.
Growth spurt.¹ An abnormal growth rate is consistent with the clinical finding of precocious puberty.
Premature skeletal development.¹ A skeletal maturity (bone age) roentgenogram should be obtained to estimate the extent of excessive stimulation and remaining growth potential.
Pubertal hormone levels.¹ Hormone levels must be consistent with those seen during puberty.

The Role of Hormone Therapy in Central Precocious Puberty

Therapy with Lupron Depot-PED can reduce gonadotropin hormones to prepubertal levels, potentially promoting skeletal growth, reversing reproductive organ growth, and stopping menses. In children with CPP, the reduction of gonadotropins allows for normal physical and psychological growth and development.²

Learn more about Lupron Depot-PED

Important Safety and Other Information

In clinical studies, the most frequent adverse event related to therapy with Lupron Depot-PED was an injection site reaction, seen in 5% of children in the combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process, allowing continued sexual development; therefore, adherence to the 4-week dosing interval must be maintained. Stimulation of sexual development may occur after the first dose or if the dose is inadequate. Lupron Depot-PED is indicated in the treatment of children with central precocious puberty. Individual results may vary. Please see the full Prescribing Information and the Patient Product Information.

You will need Adobe® Reader® to view and print the prescribing information and patient product information. To download the free reader, click on the icon below.

All photos are of models and not of users of Lupron Depot-PED or persons suffering symptoms described.


Central Precocious Puberty Main Diagnosis About Lupron Depot-PED Efficacy Dosing & Administration Safety Information Resources for Your Patients Links Procurement Questionnaire Links	Establishing the Diagnosis Prompt identification of central precocious puberty (CPP) is important. CPP results from early onset of hypothalamic secretion of gonadotropin-releasing hormone (GnRH).¹ The majority of girls presenting with precocious puberty have CPP, with underlying neurological abnormalities being unusual;¹ in boys, central nervous system lesions are more common as the underlying cause of CPP.¹ In children with CPP, GnRH analog therapy is a highly effective treatment to stop the progression of puberty and to attempt to reclaim compromised growth potential.¹ The diagnosis of CPP may require: Early pubertal changes.¹ Physical signs of puberty may include coarse, pigmented pubic hair. Girls may have premature breast development or genitalia changes (thicker vaginal mucosa). Pubertal signs in boys include growth of the penis and/or testicular growth. Growth spurt.¹ An abnormal growth rate is consistent with the clinical finding of precocious puberty. Premature skeletal development.¹ A skeletal maturity (bone age) roentgenogram should be obtained to estimate the extent of excessive stimulation and remaining growth potential. Pubertal hormone levels.¹ Hormone levels must be consistent with those seen during puberty. The Role of Hormone Therapy in Central Precocious Puberty Therapy with Lupron Depot-PED can reduce gonadotropin hormones to prepubertal levels, potentially promoting skeletal growth, reversing reproductive organ growth, and stopping menses. In children with CPP, the reduction of gonadotropins allows for normal physical and psychological growth and development.² Learn more about Lupron Depot-PED	Now you can order Lupron Depot online. Once you've set up an account, it only takes a few clicks. Find out how to dose Lupron Depot-PED based on the child's weight.

Establishing the Diagnosis

The Role of Hormone Therapy in Central Precocious Puberty

Important Safety and Other Information

References